A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9???Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
|Effective start/end date||6/1/20 → 5/31/25|
- CRISPR THERAPEUTICS, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.